Adverse effects associated with canagliflozin in initial safety trials include increased incidence of genitourinary infections, increased serum creatinine, hypoglycemia when administered with sulfonylureas or insulin, and hyperkalemia in patients with chronic kidney disease [10]. The gene discussed is INS; the disease is chronic kidney disease.